Compare CXDO & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | CRBU |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 192.4M |
| IPO Year | 1999 | 2021 |
| Metric | CXDO | CRBU |
|---|---|---|
| Price | $9.85 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $9.20 | ★ $10.75 |
| AVG Volume (30 Days) | 353.6K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 166.67 | 3.64 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $68,167,000.00 | N/A |
| Revenue This Year | $45.26 | $1.63 |
| Revenue Next Year | $13.31 | $10.93 |
| P/E Ratio | $480.50 | ★ N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $5.08 | $0.92 |
| 52 Week High | $9.89 | $3.53 |
| Indicator | CXDO | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 75.54 | 58.22 |
| Support Level | $6.04 | $1.71 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.61 | 0.13 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 98.71 | 63.27 |
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.